{"id":"NCT03247543","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD","officialTitle":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 200 and 400 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-31","primaryCompletion":"2018-10-17","completion":"2018-10-17","firstPosted":"2017-08-11","resultsPosted":"2021-07-08","lastUpdate":"2021-07-08"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["PBO"]},{"type":"DRUG","name":"200mg SPN-812","otherNames":["SPN-812"]},{"type":"DRUG","name":"400mg SPN-812","otherNames":["SPN-812"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"200mg SPN-812","type":"ACTIVE_COMPARATOR"},{"label":"400mg SPN-812","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD","primaryOutcome":{"measure":"Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5)","timeFrame":"Baseline and Week 8 (End of Study)","effectByArm":[{"arm":"Placebo","deltaMin":-11.7,"sd":1.48},{"arm":"200mg SPN-812","deltaMin":-17.6,"sd":1.43},{"arm":"400mg SPN-812","deltaMin":-17.5,"sd":1.52}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0038"},{"comp":"OG000 vs OG002","p":"0.0063"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["36847750","34523063","33971070","33750646","33600233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":103},"commonTop":["Somnolence","Fatigue","Headache","Decreased appetite","Nasopharyngitis"]}}